Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia

National Center for Research Resources (NCRR)

Status and phase: Completed; Phase 3

Conditions: Hereditary Hemorrhagic Telangiectasia

Treatments: Drug: soy protein isolate

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00004654

YALESM-8191

199/11799

Details and patient eligibility

About

OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia.

II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.

Full description

PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy protein isolate for 12 weeks. The control group receives a placebo for 12 weeks.

Patients cross to the alternate group following a 4-week washout.

Sex: All

Ages: 15+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following:
• First-degree relative with HHT
• History of recurrent epistaxis or gastrointestinal bleeding
• Three or more skin telangiectasia
• Migraine headache meeting International Headache Society criteria 3 or more times a month for more than 1 year
• No pattern of daily headaches
• No severe head trauma
• No onset of headaches after 50 years of age
• At least 1 month since migraine prophylaxis
• At least 1 month since any of the following medications: Beta blockers; Calcium channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin re-uptake inhibitors
• Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed
• Creatinine no greater than 2.5 g/dL
• No allergy to soy
• No pregnant women
• No women with intent to become pregnant